Effect of Evodiamine on immune function of allergic rhinitis rats by regulating CCL2/CCR2 signaling pathway.
- Author:
Xiaoli WANG
1
;
Wei LI
1
;
Shan ZHU
2
,
3
;
Xingchan SHI
1
;
Wei CHEN
1
Author Information
1. Department of Pediatrics, Henan Provincial Hospital of Traditional Chinese Medicine (Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou 450053, China.
2. Department of Pediatrics, Henan Provincial Hospital of Traditional Chinese Medicine (Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou 450053, China. *Corresponding author, E-mail: zhshteacher@
3. com.
- Publication Type:Journal Article
- MeSH:
Animals;
Receptors, CCR2/immunology*;
Signal Transduction/drug effects*;
Chemokine CCL2/immunology*;
Rats;
Rhinitis, Allergic/metabolism*;
Immunoglobulin E/blood*;
Quinazolines/pharmacology*;
Male;
Interferon-gamma;
Rats, Sprague-Dawley;
Interleukin-13;
Histamine;
Interleukin-4/immunology*;
Disease Models, Animal
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(4):300-307
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of Evodiamine (Evo) on the immune function of allergic rhinitis (AR) rats and the regulatory mechanism on C-C motif chemokine ligand 2 (CCL2)/ C-C motif chemokine receptor 2 (CCR2) pathway. Methods The related targets of Evo-AR-immune function were screened by network pharmacology, and the protein interaction network diagram of intersecting targets was constructed. The AR rat model was established by ovalbumin (OVA) combined with aluminium hydroxide, and the rats were divided into six groups: a normal control (NC) group, a model group, a Loratadine (LOR) group, an Evodiamine low dose (Evo-L) group, a Evodiamine high dose (Evo-H) groups, and an Evo-H combined with CCL2 group. After the last administration, the symptoms of rats in each group were scored; ELISA was applied to detect the levels of histamine, immunoglobulin E (IgE), interleukin 4 (IL-4), IL-13 and interferon γ (IFN-γ); Diff-Quick staining solution was applied to detecte the number of cells in the nasal lavage fluid (NALF); hematoxylin eosin (HE) staining was applied to observe the pathological changes of nasal mucosa tissue; real-time quantitative PCR was applied to detect the levels of CCL2 and CCR2 mRNA in tissue; Western blot was applied to detect the expression levels of CCL2, CCR2 and CXC motif chemokine ligand 8 (CXCL8) proteins in nasal mucosa. Results There were eight intersection targets of EVo-AR-immune function, and protein interaction network diagram showed that CXCL8 was the core target. Compared with the NC group, the score of nasal symptoms, the levels of histamine, IgE, IL-4 and IL-13, the numbers of eosinophil, macrophages, neutrophils, lymphocytes and total cells, the mRNA and protein expression levels of CCL2 and CCR2, and the expression of CXCL8 protein in the model group were increased, while the level of IFN-γ was decreased. Compared with the model group, the score of nasal symptoms, the levels of histamine, IgE, IL-4 and IL-13, the numbers of eosinophil, macrophages, neutrophils, lymphocytes and total cells, the mRNA and protein expression levels of CCL2 and CCR2, and the expression of CXCL8 protein in LOR and Evo groups were decreased, while the level of IFN-γ was increased. Further use of CCL2 recombinant protein for compensatory experiments revealed that the improvement effect of Evo on immune function in AR rats was reversed by CCL2. Conclusion Evo can improve the immune function of AR rats, and its mechanism may be related to the inhibition of the CCL2/CCR2 pathway.
